2025-2034 Pharmacogenomics Market Evolution: Disruptions, Innovations, and Untapped Opportunities

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Pharmacogenomics Market Through 2025?
The size of the pharmacogenomics market has seen a swift expansion in the past few years. The market is projected to surge from $8.94 billion in 2024 to reach $9.84 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.0%. The significant growth during the historical period is due to the robust economic expansion in evolving markets, heightened attention towards personalized medicine, the surge in state-of-the-art healthcare infrastructure, and escalated healthcare spending.

What's the Projected Size of the Global Pharmacogenomics Market by 2029?
The market size of pharmacogenomics is anticipated to undergo swift expansion in the coming years, surging to $14.53 billion in 2029 with a compound annual growth rate (CAGR) of 10.2%. This forthcoming growth can be linked to factors such as the increasing elderly population, the rise in chronic illness, a growing population, and the increasing need for cancer therapy. Key trends in the forecast period encompass the introduction of genome editing solutions for more in-depth examination of advanced treatments, prioritizing the integration of artificial intelligence (AI) in genomics for genetic data evaluation, continued advancements in metagenomics, strategic alliances, and shared ventures among market contenders. Additionally, the emergence of three-dimensional (3D) genomics to scrutinize effects on gene expression and functionality, new product innovations concentrating on infectious diseases and gene editing, along with the creation of psychotropic pharmacogenomics tests for informed decisions are expected to drive growth.

View the full report here:
https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report

Top Growth Drivers in the Pharmacogenomics Industry: What's Accelerating the Market?
The increasing need for precision medicine is propelling the growth of the pharmacogenomics market. Emphasizing personalized healthcare, precision medicine offers decisions, treatments, methods, and products tailored to specific patient subgroups, as opposed to a standardized approach to medication. Interest in precision medicine is growing, particularly due to its breakthrough applications not only in oncology but also in treating late-stage, genetic and rare diseases. Precision medicine's primary objective is to incorporate genetic and environmental data regarding specific diseases or their reaction to certain treatments. For example, a March 2022 article on Linchpinseo reported that leading pharmaceutical companies' rising investment in precision medicine is predicted to see a one-third increase over the next half-decade. In the US alone, precision medicine is redefining the treatment practices for the 30 million people diagnosed with type 2 diabetes, providing personalized care. Consequently, the growing need for precision medicine is the key factor propelling the pharmacogenomics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp

Which Emerging Trends Are Transforming the Pharmacogenomics Market in 2025?
Progress in technology is a significant trend gaining traction in the pharmacogenomics market. Drug manufacturers are turning their attention to multiple pharmacogenomics analysis methods in a bid to offer cost-effective solutions for screening known polymorphisms and discovering new variants. For example, in May 2022, Invitae, a medical lab organization based in the US, introduced its extended Pharmacogenomics Panel. This enlarged Invitae Pharmacogenomics (PGx) Panel, which incorporates the Mental Health Panel, offers knowledge on genetic reactions to drugs across a range of specialties such as primary care, cardiology, and oncology. Given that almost a quarter of patients experience unusual drug reactions due to genetic influence, PGx testing is poised to become commonplace. However, the integration into healthcare demands increased backup for providers to comprehend and implement PGx testing into their clinical environments.

What Are the Main Segments in the Pharmacogenomics Market?
The pharmacogenomics market covered in this report is segmented -

1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies
2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications
3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users

Subsegments:
1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing
2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR
3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis
4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry)
5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays
6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=7072&type=smp

Which Top Companies are Driving Growth in the Pharmacogenomics Market?
Major companies operating in the pharmacogenomics market include Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Xcelris Labs, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, Bayer AG, GlaxoSmithKline plc (GSK), F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas (CGBS), Dasa Group, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Laboratório Richet, Laboratório Exame, Genomika Diagnósticos

Which Regions Will Dominate the Pharmacogenomics Market Through 2029?
North America was the largest region in the pharmacogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7072

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.